TY - JOUR
T1 - Androgen deprivation therapy use and risk of mild cognitive impairment in prostate cancer patients
AU - Alonso-Quiñones, Hector
AU - Stish, Bradley J.
AU - Aakre, Jeremiah A.
AU - Hagen, Clinton E.
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
N1 - Funding Information:
Supported by the National Institutes of Health/National Institute on Aging grants U01 AG006786, U54 AG44170, and RF1 AG55151, the GHR Foundation, CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and was made possible by the Rochester Epidemiology Project (R01 AG034676).
Funding Information:
R.C.P. consults for Roche Inc., Merck Inc., Biogen Inc., Eisai Inc., GE Healthcare, and is on a DSMB for Genentech Inc. M.M.M. receives unrestricted research grants from Biogen Inc. and consults for The Brain Protection Company. The remaining authors declare no con-flicts of interest.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Introduction:We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients.Methods:We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score.Results:There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: <5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and ≥5 years versus not use (HR, 1.89; 95% CI, 0.83-4.27).Conclusion:ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.
AB - Introduction:We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients.Methods:We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score.Results:There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: <5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and ≥5 years versus not use (HR, 1.89; 95% CI, 0.83-4.27).Conclusion:ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.
KW - Cognition
KW - Longitudinal study
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85101807394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101807394&partnerID=8YFLogxK
U2 - 10.1097/WAD.0000000000000415
DO - 10.1097/WAD.0000000000000415
M3 - Article
C2 - 32960856
AN - SCOPUS:85101807394
SN - 0893-0341
VL - 35
SP - 44
EP - 47
JO - Alzheimer disease and associated disorders
JF - Alzheimer disease and associated disorders
IS - 1
ER -